Holguín prepares to start clinical trial with CBA-100

The Center for Immunology and Biopreparations of Holguín (Cibho) is getting ready to start the clinical trial of CBA-100, a natural product elaborated by two Holguín scientists committed to counteracting the consequences of SARS-CoV- 2.

CBA-100, one hundred percent organic, is an anti-inflammatory and immunostimulant biological complex demonstrated in a pre-clinical study, while its safety was confirmed in the toxicological study.

Dr. Alma Torres Gómez de Cádiz Agüero, a specialist in Comprehensive General Medicine, said that Cibho research group together with the Graduate in Biology and Major in the Ministry of Interior, Rosario Iserns Hernández, are responsible for the encapsulation of the product, while advice is received for registration in the Cuban Industrial Property Office and the completion of the file for the Center for State Control of Medicines, Equipment and Medical Devices (Cecmed).

Gómez de Cádiz added that researchers from the institution have haleped them in the organization of the laboratory, complying with good practices of quality, sterilization, microbiological study and strict observation of Biosafety regulations in the process, which is supervised by the Labiofam provincial team, led by its director, Mr. Yoandro Laffita.

The results of the CBA-100 Project were presented at different municipal, provincial, national and international events, including the Second Local Development Fair and the ANIR National Exhibition, in ExpoCuba, as a relevant scientific invention; at the Scientific Conference of the III Congress of Family Medicine, held at the Palacio de las Convenciones and at the VIII Research, Development and Innovation Conference at the University of Seville, Spain. In addition, it was published in a chapter of a book by Editorial Cientifica-3 Ciencias, Alicante, Spain.

According to the technical sheet, “CBA-100” eventually decreases viral antigenic capacity by inhibiting specific enzymes. Likewise, it would be used as a complement to resolve the situation of the deficiency of anti-inflammatory and immuno-stimulant medications, in chronic inflammatory, immunological deficiency, allergic, autoimmune and neurodegenerative conditions.

It also highlights that the economic impact of the application of "CBA-100" will be presented in the short, medium and long terms, as its safety and effectiveness are observed, and new positive results are provided.

“This totally organic product does not affect the environment, to which is added its antioxidant properties, which help improve the soil where the raw material is grown, by reducing the levels of cadmium and phosphorus, among other heavy minerals,” she explained.